Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
| Autor: | Javid Moslehi, Douglas B. Johnson, Renee K. McAlister, Andrew Gibson, Elizabeth J. Phillips, Brendan L. Mangan, Justin M. Balko |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug-Related Side Effects and Adverse Reactions
medicine.medical_treatment Programmed Cell Death 1 Receptor 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Immune system Antigen PD-L1 Neoplasms medicine Humans Pharmacology (medical) 030212 general & internal medicine Adverse effect Immune Checkpoint Inhibitors Melanoma Pharmacology Reviews‐themed Section biology business.industry Incidence Immunotherapy medicine.disease Blockade CTLA-4 Immunology biology.protein business |
| Zdroj: | Br J Clin Pharmacol |
| ISSN: | 1365-2125 |
| Popis: | Immune checkpoint inhibitors have emerged as a revolutionary treatment option for patients with various types of malignancy. Although these agents afford a significant improvement in outcomes for melanoma and other previously untreatable malignancies, their novel mechanism of action may predispose patients to immune-related adverse effects (irAEs). In the tumour neoantigen environment, these irAEs are due to the activation of the immune system by the blockade of suppressive checkpoints, leading to increases in T-cell activation and proliferation. IrAEs have been reported in almost any organ and at any point in time, even months to years after discontinuation of therapy. Certain populations with distinct physiological changes, genetic risk factors, and specific antigen exposures may be more highly predisposed to develop irAEs. This review discusses the incidence and mechanisms of irAEs and the relationship between host factors and irAE occurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text